Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19441931 | 0.73 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL30618861 | 0.69 | PTGER4 (0.65) | PTGER4ANO1 | |
| SCHEMBL14930416 | 0.65 | PNMT (0.43) | RAB9A | |
| SCHEMBL5455584 | 0.65 | LIMK1 (0.38) | — | |
| SCHEMBL19835515 | 0.63 | CA1 (0.39) | HTR2CNPC1RAB9A | |
| SCHEMBL31246225 | 0.63 | CA1 (0.39) | HTR2CNPC1RAB9A | |
| SCHEMBL9122886 | 0.63 | CA1 (0.39) | HTR2CNPC1RAB9A | |
| SCHEMBL16584601 | 0.62 | PARP1 (0.37) | HTR2CNPC1RAB9A | |
| SCHEMBL14925534 | 0.62 | PRKDC (0.36) | — | |
| SCHEMBL22817550 | 0.62 | PRKDC (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590103-B2 | Polymorph of EP4 receptor antagonist, preparation method therefor and use thereof | Shanghai Yuyao Biotech Ltd. (CN) | 2026-03-31 | — | — | US | disclosed |
| CN-113087719-B | Polymorphic substance of EP4 receptor antagonist and preparation method and application thereof | 上海宇耀生物科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-113087719-B | Polymorphic substance of EP4 receptor antagonist and preparation method and application thereof | 上海宇耀生物科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230074179-A1 | POLYMORPH OF EP4 RECEPTOR ANTAGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Yuyao Biotech Ltd. (CN) | 2023-03-09 | — | — | US | disclosed |
| EP-4101854-A1 | POLYMORPH OF EP4 RECEPTOR ANTAGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Yuyao Biotech Ltd. (CN) | 2022-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230074179-A1 | POLYMORPH OF EP4 RECEPTOR ANTAGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | PTGER4, PTGER1, FFAR4 | PTGER4 1/4885PDE1B 886/4885KDM4E 2304/4885 |
| US-12590103-B2 | Polymorph of EP4 receptor antagonist, preparation method therefor and use thereof | PTGER4, PTGER1, FFAR4 | PTGER4 1/4885PDE1B 1141/4885KDM4E 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.